Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/25/2025

Rheumatoid Arthritis Flare Management

Symptoms and Diagnosis

  • The American College of Rheumatology suggests that increased joint pain, swelling, and stiffness in previously affected joints are symptoms of RA flare 2, 3
  • Fatigue and general malaise are common symptoms of RA flare 2
  • Elevated inflammatory markers, such as CRP and ESR, are associated with RA flare 3
  • Decreased functional capacity and quality of life are outcomes of RA flare 3

Treatment Options

  • The European League Against Rheumatism recommends colchicine as a first-line treatment for RA flares, with a loading dose of 1 mg followed 1 hour later by 0.5 mg on day 1 1
  • Colchicine is most effective when given within 12 hours of symptom onset, and should be avoided in patients with severe renal impairment or those taking strong P-glycoprotein/CYP3A4 inhibitors 1
  • NSAIDs are effective for pain and inflammation control, but should be used with caution in patients with severe renal impairment, and a proton pump inhibitor should be considered if appropriate 1
  • Oral corticosteroids, such as prednisolone 30-35 mg/day for 3-5 days, are equivalent in effectiveness to NSAIDs in clinical trials, and are particularly useful for multi-joint involvement 1

Long-Term Management

  • The American College of Rheumatology recommends resuming or adjusting DMARD therapy based on disease activity after flare resolution 3, 4
  • A treat-to-target approach aiming for remission or low disease activity is recommended, with monitoring of disease activity using validated measures such as SDAI and CDAI 3, 4
  • For patients with frequent flares, adjusting baseline therapy is recommended 4

Special Considerations

  • The American Heart Association notes that NSAIDs may increase cardiovascular risk, especially with prolonged use 5
  • Long-term corticosteroid use increases the risk of cataracts, osteoporosis, and potentially cardiovascular disease 2
  • Colchicine and NSAIDs should be avoided in patients with severe renal impairment, and drug interactions should be considered when prescribing colchicine 1